David Hung, Nuvation Bio CEO
May 23, 2024 05:00 PM EDT
R&D
China

Nu­va­tion Bio shares piv­otal Chi­na da­ta for can­cer drug from An­Heart buy­out

Amber Tong

Senior Editor

Nu­va­tion Bio show­cased longer-term Phase 2 da­ta around the next-gen ROS1 in­hibitor it hopes will give Pfiz­er and Bris­tol My­ers Squibb a run for their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Au­toim­mune CAR-T da­ta dump: Kyver­na, Ca­balet­ta shares fall af­ter un­veil­ing ear­ly-stage re­sults

Stephen Squin­to talks writ­ing checks and next-gen obe­si­ty drugs as JP Mor­gan clos­es first $500M+ biotech fund

Nurix’s pro­tein de­grad­er over­comes re­sis­tance to BTK mu­ta­tions in small leukemia study

Gilead can­cer drug ma­grolimab showed wor­ry­ing trends around death

Up­dat­ed: Telix Phar­ma­ceu­ti­cals pulls Nas­daq list­ing plans just be­fore trad­ing was to start

sponsored

De-risk­ing the pa­tient jour­ney in cell ther­a­pies: Six key con­sid­er­a­tions

A service from the Financial Times